<DOC>
	<DOCNO>NCT01305837</DOCNO>
	<brief_summary>The purpose study determine whether cyclic oral methylprednisolone every month effect intrathecal inflammation patient suffer progressive multiple sclerosis .</brief_summary>
	<brief_title>Cyclic Oral Methylprednisolone Trial Multiple Sclerosis</brief_title>
	<detailed_description>Multiple Sclerosis ( MS ) chronic inflammatory demyelinate disease central nervous system ( CNS ) . It presumably T-cell mediate common non-traumatic cause disability affect young people . 85 % MS cause start relapse remit MS ( RRMS ) 15 % primary progressive MS ( PPMS ) . It find 10 year 40-45 % RRMS patient convert progressive state disease , secondary progressive MS ( SPMS ) . Until recently believe progression see MS occur axonal loss neurodegeneration could occur independently inflammation . Now neuropathology study show close association inflammation neurodegeneration stage MS - also progressive form MS. Osteopontin ( OPN ) extracellular matrix protein chemokine , cytokine intergrin property . It multiple immunological function secrete activated macrophage , leukocyte activate T lymphocyte . It present extracellular fluid up-regulated site inflammation . Increased level OPN report cerebrospinal fluid ( CSF ) patient MS . The main aim study analyze effect cyclic oral methylprednisolone intrathecal inflammation patient suffer progressive multiple sclerosis measure OPN CSF . Second investigator look aims intrathecal inflammation , neurodegeneration , demyelination safety .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Age 18 65 year old Progressive form MS ( Eg . primary secondary progressive MS ) Duration progressive phase least 1 year Progression least 1 EDSS point last 2 year least Â½ EDSS point patient EDSS &gt; 5,5 Progressin 2 FS point EDSS &lt; /= 6,5 Signed inform consent write authority Pregnancy breast feed Lack secure contraception woman childbearing age ( hormonal intrauterine device ) Attack last month previous inclusion Treatment methylprednisolone cyclic methylprednisolone 3 previous month inclusion Treatment interferonbeta , Glatiramer acetate , immunglobulin G immunomodulating treatment 3 previous month inclusion Treatment Mitoxantrone , ciclofosfamide , Azathioprin immunosuppressive treatment 6 previous month inclusion Previous treatment drug treat physician find could influence study result Diseases associate immune defect Treatment anticoagulant acetyl salicyl acid Malignancy Diabetes Mellitus Renal insufficiency SCreatinine &gt; 150 mmol/l Acute chronic infection hepatitis B og C virus , HIV infection treat physician find relevant Psychiatric illness condition impair collaboration patient participate study Contraindication MRI Hypersensitivity methylprednisolone Osteoporosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>multiple sclerosis</keyword>
	<keyword>methylprednisolone</keyword>
	<keyword>osteopontin</keyword>
	<keyword>inflammation</keyword>
	<keyword>demyelinate</keyword>
</DOC>